Background:
Receptor Tyrosine Kinases (RTK) are the main family of cell surface receptors for
growth factors, hormones and cytokines which are responsible for cell growth and differentiation and are considered
as an important therapeutic target in cancer.
Objective:
The aim of this study was to design, synthesise and conduct the biological evaluation of benzimidazole/
benzoxazole substituted triazolotriazines as new anticancer agents.
Methods:
A series of benzimidazolyl and benzoxazolyl-linked triazolotriazines 8a-e and 9a-e were synthesized
as receptor tyrosine kinase inhibitors. Target compounds were evaluated in HGF-induced cell proliferation assay
in A549, MCF-7, HepG2 and MDA-MB-231 cancer cells.
Results:
Hepatocellular carcinoma was the most sensitive cell line towards the tested compounds and 8e was the
most potent one on HepG2 cells with an IC50 value of 5.13µM which was close to crizotinib (HepG2 IC50 =
4.35µM) as a standard c-Met kinase inhibitor. c-Met kinase assay of 8e showed that this compound is not capable
of inhibiting this enzyme and subsequently molecular docking confirmed the low affinity of 8e towards c-
Met active site and its possible anticancer mechanism through VEGFR-2 inhibition.
Conclusion:
Further in silico predictions revealed that 8e can be a drug candidate with favorable pharmacokinetic
properties.
